GSA Capital Partners LLP Has $490,000 Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

GSA Capital Partners LLP boosted its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 1,285.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 354,815 shares of the company’s stock after acquiring an additional 329,205 shares during the quarter. GSA Capital Partners LLP owned 0.14% of Lyell Immunopharma worth $490,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of LYEL. ProShare Advisors LLC boosted its position in Lyell Immunopharma by 9.3% during the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after acquiring an additional 4,170 shares during the period. Acadian Asset Management LLC acquired a new stake in Lyell Immunopharma during the 1st quarter worth about $173,000. Price T Rowe Associates Inc. MD boosted its position in Lyell Immunopharma by 1.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after acquiring an additional 92,594 shares during the period. Caxton Associates LP lifted its holdings in shares of Lyell Immunopharma by 359.1% during the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock valued at $389,000 after buying an additional 136,611 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Lyell Immunopharma in the 1st quarter valued at approximately $64,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on LYEL shares. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, November 12th. Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and lowered their price target for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $1.11 on Wednesday. The stock has a market capitalization of $309.94 million, a P/E ratio of -1.41 and a beta of -0.47. The stock has a 50 day moving average price of $1.21 and a two-hundred day moving average price of $1.65. Lyell Immunopharma, Inc. has a 12-month low of $0.85 and a 12-month high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. The firm had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.